Platelet-activating factor and its basic metabolic enzymes in blood of naive HIV-infected patients

Angiology

Volumn 63, Issue 5, 2012, Pages 343-352

  Tsoupras, Alexandros B ^a   Chini, Maria ^b   Mangafas, Nikos ^b   Tsogas, Nikos ^b   Stamatakis, George ^a   Tsantila, Nektaria ^a   Fragopoulou, Elizabeth ^c   Antonopoulou, Smaragdi ^c   Gargalianos, Panagiotis ^d   Demopoulos, Constantinos A ^a   Lazanas, Marios C ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c HAROKOPIO UNIVERSITY   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

human immunodeficiency virus (HIV); lyso PAF acetyltransferase (lyso PAF AT); naive patients; PAF; PAF cholinephosphotransferase (PAF CPT)

Indexed keywords

1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ACETYL COENZYME A ACETYLTRANSFERASE; CHOLINEPHOSPHOTRANSFERASE; LIPOPROTEIN; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VIVO STUDY; LEUKOCYTE; MALE; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RISK FACTOR; SYMPTOM; VIRUS LOAD;

EID: 84861863864     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711420608     Document Type: Article

References (46)

1. Demopoulos CA, Pinckard RN, Hanahan DJ.. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl-choline as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 ; 254 (19). 9355-9358
2. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM.. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002 ; 30(5 suppl): S294 - S301
3. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM.. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003 ; 40 (6). 643-672
4. Snyder F.. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995 ; 1254 (3). 231-249
5. Francescangeli E, Boila A, Goracci G.. Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res. 2000 ; 25 (5). 705-713
6. Snyder F.. CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997 ; 1348 (1-2). 111-116
7. Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S, Demopoulos CA.. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007 ; 2007: 27683
8. Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009 ; 42 (1-2). 44-49
9. Imagawa M, Mimata H, Takahashi SI, Nakagawa M, Nomura Y, Ogata J.. Modulation of platelet-activating factor synthesis by recombinant interferon-α in human renal cell carcinoma. Urol Int. 1996 ; 57 (1). 11-16
10. Gimenez R, Aguilar J.. Cytidine (5-) diphosphocholine induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats. Neurosci Lett. 2001 ; 299 (3). 209-212
11. Karasawa K.. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta. 2006 ; 1761 (11). 1359-1372
12. Montrucchio G, Alloatti G, Camussi G.. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000 ; 80 (4). 1669-1699
13. Demopoulos CA, Karantonis HC, Antonopoulou S.. Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003 ; 105 (11). 705-716
14. López-Novoa JM.. Potential role of platelet activating factor in acute renal failure. Kidney Int. 1999 ; 55 (5). 1672-1682
15. McManus LM, Pinckard RN.. PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med. 2000 ; 11 (2). 240-258
16. Kasperska-Zajac A, Brzoza Z, Rogala B.. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov. 2008 ; 2 (1). 72-76
17. Nathan N, Denizot Y, Huc MC, et al. Elevated levels of paf-acether in blood of patients with type 1 diabetes mellitus. Diabete Metab. 1992 ; 18 (1). 59-62
18. Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA.. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009 ; 9 (4). 390-399
19. Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, Abellán Alemán A, Rubio del Barrio R.. Platelet-activating factor antagonists. Allergol Immunopathol. 1997 ; 25 (5). 249-258
20. Tsoupras AB, Chini M, Tsogas N, et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?. AIDS Res Hum Retroviruses. 2008 ; 24 (8). 1079-1086
21. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA.. In vitro and in vivo effects of statins on platelet activating factor and its metabolism. Angiology. 2011 ; 62 (3). 209-218
22. Perry SW, Hamilton JA, Tjoelker LW, et al. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem. 1998 ; 273 (28). 17660-17664
23. Biancone L, Cantaluppi V, Boccellino M, et al. Motility induced by human immunodeficiency virus-1 tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol. 1999 ; 155 (5). 1731-1739
24. Doublier S, Zennaro C, Spatola T, et al. HIV-1 tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS. 2007 ; 21 (4). 423-432
25. Martin M, Serradji N, Dereuddre-Bosquet N, et al. PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother. 2000 ; 44 (11). 3150-3154
26. Bradford MM.. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254
27. Bligh EG, Dyer WJ.. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 ; 37 (8). 911-917
28. Antonopoulou S, Demopoulos CA, Iatrou C, Moustakas G, Zirogiannis P.. Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem. 1994 ; 26 (9). 1157-1162
29. Currier JS.. Update on cardiovascular complications in HIV infection. Top HIV Med. 2009 ; 17 (3). 98-103
30. Malvestutto CD, Aberg JA.. Coronary heart disease in people infected with HIV. Cleve Clin J Med. 2010 ; 77 (8). 547-56
31. Paraskevas KI, Katsiki N, Tzovaras AA, Koupidis SA, Mikhailidis DP.. Peripheral arterial disease and HIV-positive patients. Angiology. 2011 ; 62 (1). 7-9
32. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008 ; 300 (1). 51-59
33. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010 ; 53 (1). 102-6
34. Bernatchez PN, Winstead MV, Dennis EA, Sirois MG.. VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A2. Br J Pharmacol. 2001 ; 134 (1). 197-205
35. Francescangeli E, Domanska-Janik K, Goracci G.. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J Lipid Mediat Cell Signal. 1996 ; 14 (1-3). 89-98
36. Baker RR, Chang HY.. The potential for platelet-activating factor synthesis in brain: properties of cholinephosphotransferase and 1-alkyl-sn-glycero-3-phosphate acetyltransferase in microsomal fractions of immature rabbit cerebral cortex. Biochim Biophys Acta. 1993 ; 1170 (2). 157-164
37. Francescangeli E, Boila A, Goracci G.. Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res. 2000 ; 25 (5). 705-713
38. Ibe BO, Portugal AM, Usha Raj J.. Metabolism of platelet activating factor by intrapulmonary vascular smooth muscle cells. Effect of oxygen on phospholipase A2 protein expression and activities of acetyl-CoA acetyltransferase and cholinephosphotransferase. Mol Genet Metab. 2002 ; 77 (3). 237-248
39. Francescangeli E, Grassi S, Pettorossi VE, Goracci G.. Activation of PAF-synthesizing enzymes in rat brain stem slices after LTP induction in the medial vestibular nuclei. Neurochem Res. 2002 ; 27 (11). 1465-1471
40. Khovidhunkit W, Memon RA, Shigenaga JK, et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism. 1999 ; 48 (12). 1524-1531
41. Grunfeld C.. Dyslipidemia and its treatment in HIV infection. Top HIV Med. 2010 ; 18 (3). 112-118
42. Scanu AM, Edelstein C.. HDL: bridging past and present with a look at the future. FASEB J. 2008 ; 22 (12). 4044-4054
43. Squinto SP, Braquet P, Block AL, Bazan NG.. Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes. J Mol Neurosci. 1990 ; 2 (2). 79-84
44. Lima RG, Moreira L, Paes-Leme J, et al. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. AIDS Res Hum Retroviruses. 2006 ; 22 (8). 763-769
45. Kucera LS, Iyer N, Leake E, et al. Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Res Hum Retroviruses. 1990 ; 6 (4). 491-501
46. Tsoupras AB, Chini M, Tsogas N, et al. Effects of highly active antiretroviral therapy (HAART) on platelet activating factor (PAF) metabolism in HIV-infected patients: in vivo results. J Int AIDS Soc. 2008 ; 11 (suppl 1). P105